Where the science of curing Type 1 diabetes actually stands: islet and stem-cell therapies, beta-cell regeneration, immunotherapies, and disease-modifying trials, in plain language.
Newest public articles in this topic cluster.
Highest growth-index pieces and decision-engine promote picks — still evidence-labeled, not medical advice.
Scientists are exploring ways to replace insulin-producing cells using new technologies and cellular therapies. While early results show promise, these approaches are still in early testing phases.
Scientists are making progress on stem cell therapies that could restore insulin production in Type 1 diabetes. But major hurdles remain before these treatments become widely available.
A new clinical trial has generated interest in the Type 1 diabetes community. Here's what we know about the approach, its potential, and the realistic picture of where it stands.
Researchers are working to create insulin-producing cells from stem cells in early clinical trials. Here's what the emerging research shows and what we still need to learn.
Researchers are exploring pig islet transplants as a potential solution to the shortage of human donor cells. Early studies show promise, but significant challenges remain before this approach becomes available to patients.
For decades, researchers believed that once insulin-producing beta cells were destroyed in Type 1 diabetes, they were gone for good. New evidence suggests the picture is far more complex—and opens doors to transformative therapies.
For decades, researchers believed that lost beta cells could never come back. New work is challenging that assumption and exploring whether the body's own cells might be coaxed to regrow.
Scientists are studying how the body might regenerate insulin-producing cells. Here's what current research is exploring—and why it matters.
A new treatment called teplizumab can delay the onset of Type 1 diabetes in people at high risk. Here's what the evidence shows about how it works and what it means for patients and families.
If type 1 diabetes runs in your family, your risk is significantly higher. Early screening through a simple blood test may help identify the condition before insulin becomes necessary.
New evidence suggests that beta cells may not be permanently damaged in early Type 2 diabetes. Early action through lifestyle changes may help restore some pancreatic function.
A new study from USC suggests people with type 1 diabetes may face increased risk for bladder cancer. Researchers are working to understand why this connection exists.
Scientists are growing insulin-producing cells from stem cells to study Type 1 diabetes and develop potential transplant therapies. Recent clinical progress shows these lab-grown islets may one day offer a more permanent treatment option.
New clinical guidelines highlight how screening for early signs of Type 1 diabetes and emerging immunotherapy treatments are helping delay disease onset in at-risk children. Understanding these advances can help families make informed decisions about their care.
A major safety review of immunotherapy trials spanning up to 18 years found no increased risks from experimental type 1 prevention treatments. The findings clear the path for continued research into delaying disease onset.
A bill in Congress could change how insulin-producing islet cell transplants are regulated in the US. Here's what the proposal aims to do and why it matters to the Type 1 community.
A new study in diabetic rats found that berberine, a compound from a traditional medicinal plant, reduced blood sugar and showed signs of restoring damaged pancreatic cells. These early findings suggest a potential avenue for research, though human studies are still needed.
Recent studies suggest that many beta cells in type 2 diabetes may not be permanently dead, but rather inactive. Understanding this distinction could reshape how we think about the disease.
A YouTube video promoting stem cell therapy for diabetes lacks the scientific evidence needed to evaluate its effectiveness. Here's what you should know about assessing unproven treatments.
At the American Diabetes Association's 2025 scientific conference, Vertex Pharmaceuticals presented data on zimislecel, an experimental therapy designed to work with the immune system in Type 1 diabetes. The findings add to ongoing research into cell-based approaches for the condition.
Scientists have identified a protein that enhances how the body uses insulin, and early lab work suggests a small peptide derived from it may help improve blood sugar control in Type 1 diabetes.
The first FDA-approved treatment to delay the onset of Type 1 diabetes is changing how doctors approach the disease. Here's what families need to know about screening, staging, and this emerging therapy.
Researchers are exploring nanomedicines, cell regeneration techniques, and transplantation strategies to restore the insulin-producing cells damaged by Type 1 diabetes. Here's what the latest research shows.
A 42-year-old patient received transplanted cells modified with CRISPR gene editing to resist immune attack. Early results suggest the approach may help the body produce insulin again.
New research in mice reveals that omega-3 fatty acids alter gut bacteria in ways that could calm inflammation in the pancreas. Scientists are mapping the microbial and chemical changes involved.
Scientists have identified a protein in immune cells that may play a key role in triggering type 1 diabetes. Blocking this protein in the laboratory prevented diabetes while leaving other parts of the immune system intact.
Researchers are developing treatments designed to preserve or restore the pancreas's ability to produce insulin by protecting beta cells from immune attack. These therapies aim to change the course of Type 1 diabetes at any stage of the disease.
Scientists combined a plant compound with a common diabetes medication and observed significant growth in insulin-producing cells in a laboratory study. Here's what this early work means for the Type 1 diabetes community.
Researchers are exploring whether transplanted insulin-producing cells could help people with Type 1 diabetes produce their own insulin again. A small early study presented recent results worth understanding.
Researchers found that a naturally occurring molecule called adenosine may help islet cells withstand the stress of transplantation. Early lab results suggest this approach could improve the success of islet transplants for Type 1 diabetes.
Researchers found that tiny cell-derived particles called extracellular vesicles can protect insulin-producing beta cells after transplantation. The finding might eventually simplify how doctors prepare islets for transplant and improve outcomes for patients.
A new medication called teplizumab (Tzield) can slow the progression of type 1 diabetes in children and young adults. Here's what families need to know about this disease-modifying therapy.
Recent clinical trials reveal that transplanted insulin-producing cells grown from stem cells can help some people with Type 1 diabetes achieve better blood sugar control. Researchers are testing different approaches to make these treatments safer and more practical.
Researchers have engineered insulin-producing cells that may survive in the body without immunosuppressive drugs. Early results from one patient show promise, but much more research is needed.
A new study using stem cell infusion showed promising results in a small group of Type 1 diabetes patients, with most reporting reduced or eliminated insulin requirements. Researchers are working to understand how the approach works and whether findings will hold up in larger trials.
Scientists are exploring different approaches to help people with Type 1 diabetes produce their own insulin or manage related conditions. Here's what early research is showing.
Researchers are exploring several experimental strategies to help the body produce insulin again, from stem cell transplants to improved islet grafting techniques. Here's what the latest research shows.
Scientists have shown that chemicals can prompt beta cells to multiply—a shift from the old belief that these cells couldn't regenerate. Early research into beta cell regeneration could one day lead to new treatment approaches for Type 1 diabetes.
Several companies are developing potential treatments for Type 1 diabetes. Here's what the clinical trial process actually looks like and why it takes years to bring new therapies to patients.
Disease-modifying therapies aim to slow or stop Type 1 diabetes before symptoms appear. JDRF researchers are connecting screening efforts with clinical testing to make these treatments available to people in early stages of the disease.
For a century, insulin has been the lifeline for people with Type 1 diabetes. Now, researchers are working on immunotherapies designed to preserve the body's remaining insulin production—potentially making diabetes easier to manage.
Researchers have successfully transplanted insulin-producing cells into a patient with type 1 diabetes without triggering immune rejection. While early results are modest, the approach represents a meaningful step toward cell-based therapies.
Scientists are exploring multiple approaches to address the root cause of Type 1 diabetes, including immune system resets, stem cell-derived insulin-producing cells, and improved monitoring of people at risk. While early results in animal studies are promising, researchers emphasize these are still years away from wid…
Researchers are using genetically modified cells derived from stem cells to create insulin-producing cells that can evade the immune system's attack. Early results from one patient show promise, though much more research is needed.
Vertex Pharmaceuticals is testing an approach that replaces damaged insulin-producing cells. Early participants have achieved insulin independence, but the therapy is still new and requires careful monitoring.
A small study shows that CGM data could reveal whether teplizumab is working weeks or months before standard blood tests do. Researchers are now investigating whether this insight might improve how we monitor the drug's impact in children with early-stage Type 1 diabetes.
Scientists are advancing stem cell therapies that can produce insulin-making cells for transplant. Early results show some patients achieved insulin independence, but significant challenges remain before this approach becomes widely available.
A new clinical trial tested whether insulin-producing cells from specially bred pigs could be safely transplanted into people with Type 1 diabetes. Early results suggest the approach may be viable, though more research is needed.
Recent research shows that insulin-producing beta cells' own stress responses—not just immune system attacks—play a central role in Type 1 diabetes. This discovery is reshaping how scientists think about prevention and treatment.
A small clinical trial of stem cell treatment has restored insulin production in participants with Type 1 diabetes. Researchers are exploring whether this approach could reduce or eliminate the need for insulin injections.
A biotech company has published early results from a small group of people who received transplants of laboratory-made beta cells. While outcomes were encouraging, the approach still requires patients to take immunosuppressive medications.
Scientists can now grow insulin-producing islet cells in the laboratory and transplant them into people with Type 1 diabetes. Here's what this emerging research means and what questions remain.
A small biotechnology company called Enselin is testing an early-stage implantable device that combines insulin-producing cells with protective technology. Here's what the first safety results tell us—and what they don't.
Researchers analyzed tiny particles in blood plasma and found a set of proteins that could help predict type 1 diabetes before symptoms appear. The approach identified hundreds of new potential warning signs.
A new study reveals that certain types of immune cells in the pancreas can help beta cells survive and function better—without attacking them. This discovery offers a potential pathway for protecting remaining beta cells in people with Type 1 diabetes.
Early findings suggest a new cell therapy called zimislecel may help some people with Type 1 diabetes reduce their insulin dependence. Researchers are working to understand how this approach works and who might benefit most.
Doctors at the University of Pennsylvania are investigating how stem cell therapy might help manage type 1 diabetes symptoms. Early research suggests this approach could offer a new avenue for treatment, though more work is needed.
Helmholtz Munich has received funding to investigate how Type 1 diabetes develops in adults, potentially opening new pathways for early detection and intervention.
A biotechnology company is testing a tiny implantable pouch designed to protect insulin-producing cells from the immune system. Early results suggest the approach could help restore insulin production in people with Type 1 diabetes.
Decades of research into regenerating insulin-producing beta cells is reaching patients. New clinical trials show that transplanted stem cell-derived beta cells can restore insulin production and improve blood sugar control in people with Type 1 diabetes.
New treatments aim to stop the immune system from attacking insulin-producing cells. Researchers are testing immunotherapies at different stages—before diabetes develops, right after diagnosis, and beyond.
A clinical trial of transplanted insulin-producing cells delivered directly to the liver has shown encouraging early results, with most recipients producing their own insulin. Researchers are exploring whether this approach could eventually offer an alternative to insulin therapy.
Scientists worldwide are investigating whether stem cell research could offer new approaches to Type 1 diabetes. An expert in the field discusses what collaboration and current evidence reveal about this emerging area.
A preclinical study suggests that using multiple strategies together may help slow the advancement of type 1 diabetes. While early-stage research, the findings point to a promising direction for future development.
Researchers are exploring immunotherapy approaches that may help preserve insulin-producing cells and delay the onset of Type 1 diabetes. These efforts represent a significant step in the path toward better treatments, though much work remains.
New research shows that pancreatic beta cells activate different defense mechanisms depending on what's attacking them—whether it's a viral signal or direct DNA damage. Understanding these distinct responses could help researchers develop better ways to protect insulin-producing cells.
A new transplant-based treatment being studied at University of Chicago Medicine is allowing some patients to reduce or stop insulin injections. Early results from three trial participants offer a potential path forward for managing Type 1 diabetes.
Researchers have developed a technique to grow uniform clusters of insulin-producing cells that could be used in transplantation devices. The advance addresses a key challenge in making cell replacement therapy practical for people with Type 1 diabetes.
Scientists at Tech Launch Arizona have created a line of human stem cells engineered to avoid immune detection. If successful in clinical use, this approach could eventually help restore insulin production in people with Type 1 diabetes.
Multiple research teams are working on stem cell approaches that could one day restore the body's ability to produce insulin. While progress is real, experts emphasize we're still years away from a widely available treatment.
Researchers found that a fibrin-based material containing tiny blood vessel fragments helps transplanted insulin-producing cells survive and function better when placed under the skin in diabetic rats.
A long-time insulin pen user tested the Omnipod 5 automated insulin pump system for over two months. Here's what they learned about the technology's strengths, limitations, and real-world challenges.
A pediatric endocrinologist discusses what we know about immunotherapy approaches for children who show early signs of developing Type 1 diabetes. Learn what the research landscape currently looks like and why early intervention matters.
Researchers in Boston are testing thousands of chemical compounds to find ones that might encourage the body's insulin-producing beta cells to multiply and regrow. While still early-stage, this approach represents a shift in how scientists think about treating Type 1 diabetes.
If type 1 diabetes runs in your family, your risk is significantly higher. A simple blood test can detect the condition long before symptoms appear.
A recently published small study reports that patients who received stem cell therapy were able to go without insulin injections for several months. While early results are encouraging, much more research is needed to understand whether this approach could offer a path forward for people with Type 1 diabetes.
Researchers found that blocking a protein called NAMPT may help protect insulin-producing beta cells from immune attack in Type 1 diabetes. The discovery, made in mice and human tissue, points to a potential new approach for slowing disease progression.
A new study reveals that lab-grown insulin-producing cells respond very differently to low-oxygen conditions than natural islets do. Understanding these differences could help scientists design better transplants for Type 1 diabetes.
Vertex presents data from Phase I/II stage of trial for type 1 diabetes Clinical Trials Arena
Sana Biotechnology's research shows that gene-modified pancreatic cells remain functional and continue making insulin over time. The findings represent progress in exploring whether edited cells could one day help people with Type 1 diabetes.
Pancreas transplantation offers real benefits for people with Type 1 diabetes, but keeping grafts healthy requires better ways to detect problems early. New molecular tools are changing how doctors monitor transplanted pancreases.
From inhaled insulin to medications that reduce carb counting, researchers are developing new options to make daily diabetes management easier. Here's what the science shows so far.
A new international position statement outlines when delivering insulin directly into the abdomen may help people with Type 1 diabetes achieve better blood sugar control and fewer dangerous low blood sugar episodes.
A clinical trial is evaluating whether implanting insulin-producing cells under the skin could help people with Type 1 diabetes manage their condition. Here's what the early research shows.
Researchers at Harvard are exploring stem cell therapy as a potential new treatment approach for Type 1 diabetes. While early-stage research shows promise, it's important to understand what scientists have actually discovered so far.
A clinical trial called Forward is testing whether stem cells engineered in the laboratory to produce insulin might reduce or eliminate the need for insulin injections in people with Type 1 diabetes. Early results suggest the approach warrants further study, though much research remains.
Researchers developed a thin, multilayered protective coating for pancreatic islet transplants that may help the immune system tolerate the transplanted cells. Early results in mice suggest the coating could improve transplant survival and restore blood sugar control.
Researchers are exploring a new class of molecules designed to retrain immune cells that attack beta cells. Here's what we know about this early-stage approach.
Researchers are exploring stem cell transplants and immunotherapy as potential approaches to help people with Type 1 diabetes. Here's what's being studied and why this work matters.
Beta cell regeneration is a question many people with Type 1 diabetes wonder about. Here's what we know about where this research stands today.
A mother shares her 8-year-old son's journey with an experimental stem cell treatment and the changes she observed in his insulin needs and daily life. This is one family's story—not a clinical study.
A newly FDA-approved injectable drug called teplizumab may slow the progression to symptomatic Type 1 diabetes for people in early stages of the disease. Here's what the approval means for patients and families.
Dr. Nicole Sheenan from Cincinnati Children's Hospital shares insights on new advances in identifying and preventing type 1 diabetes in children.
From early detection through autoantibody screening to innovative device technology and immunomodulatory treatments, the landscape of pediatric Type 1 diabetes management is evolving. Here's what's happening in research and clinical practice.
The FDA has approved teplizumab as the first disease-modifying therapy shown to delay the onset of stage 3 type 1 diabetes in children and adolescents. Here's what the evidence shows and what it means for families.
A new study reveals that patients are willing to tolerate potential side effects if novel therapies offer meaningful improvements to their diabetes management. The finding highlights an important shift in how people think about treatment trade-offs.
A quarter-century into cell transplantation for Type 1 diabetes, researchers are learning how to overcome early limitations and move closer to sustained remission. Here's where the science stands.
Researchers are exploring immunotherapy and stem cell approaches to address the root causes of Type 1 diabetes. Here's what early research suggests about these emerging strategies.
Researchers are exploring islet transplantation as a way to restore insulin-producing function in people with Type 1 diabetes. Understanding how this approach works—and its current limitations—can help patients and families evaluate emerging options.
City of Hope is enrolling adults recently diagnosed with Type 1 diabetes in a study exploring whether denosumab, an FDA-approved osteoporosis medication, might help preserve remaining beta cell function.
Researchers and companies developing next-generation islet cell treatments face rigorous regulatory and manufacturing hurdles. A new guide outlines what it takes to bring these complex therapies from laboratory to patient.
For a century, insulin has been the backbone of Type 1 diabetes management—but it has real limitations. A new research initiative called ATIC is exploring immunotherapy approaches that could address the disease at its source.
A new study shows that access to a disease-modifying therapy has shifted how and who gets tested for islet autoantibodies—the early warning signs of Type 1 diabetes. But important gaps remain.
Researchers are working on transplanting insulin-producing cells into people with Type 1 diabetes. A major challenge has been protecting these new cells from the immune system. Recent work suggests progress on this problem—but we're still in early stages.
Researchers are exploring ways to modify stem cells so the immune system won't attack transplanted insulin-producing cells, potentially reducing the need for immune-suppressing drugs in future Type 1 diabetes treatments.
Researchers are testing tegoprubart, a medication that may help reduce the burden of immunosuppressive drugs needed after islet cell transplantation. Early results suggest potential for making this minimally invasive procedure safer and more accessible.
Scientists are exploring how extracellular vesicles—microscopic particles released by cells—might offer new ways to spot beta cell damage and track disease progression in Type 1 diabetes.
Sierra's story shows why knowing your family history of Type 1 diabetes can lead to early screening and access to therapies that may delay disease onset.
A major Type 1 diabetes screening initiative is shifting toward at-home testing methods and expanding who can participate. Here's what researchers are learning about making early detection more accessible.
Breakthrough T1D is expanding its focus on early detection, immunotherapy, and cell replacement approaches—all of which depend on people willing to participate in research studies.
A panel of international researchers convened to explore what prevention and remission might mean for people at risk of or living with Type 1 diabetes. The discussion highlighted the evolving landscape of T1D research.
At a 2023 JDRF symposium, researchers, clinicians, and people living with Type 1 diabetes shared why intercepting and delaying the disease could transform millions of lives. Here's what that vision means in practice.
Researchers are studying pancreatic tissue from people with Type 1 diabetes to understand what happens inside the organ during the disease. These insights are fueling new approaches to preserve insulin production and potentially reverse the condition.
Multiple research groups are exploring stem cell transplants as a potential functional cure for Type 1 diabetes. While progress is genuine, experts emphasize the importance of realistic expectations about when these therapies might become available.
Before any new Type 1 diabetes treatment reaches patients, it must pass through years of research and rigorous testing. Here's how the drug development and approval process actually works.
City of Hope is recruiting newly diagnosed adults for a study testing whether denusumab, an FDA-approved osteoporosis medication, might help protect and regenerate insulin-producing cells in early Type 1 diabetes.
Researchers are evaluating whether implanting islet cells—the insulin-producing tissue from the pancreas—into the forearm could help people with Type 1 diabetes manage their blood sugar. The work is in very early stages.
New research from Vertex suggests that transplanted insulin-producing cells can restore blood sugar control in some people with Type 1 diabetes, though the approach currently requires immunosuppressant drugs.
Vertex Pharmaceuticals is developing a therapy that replaces insulin-producing cells, with early results showing promise for people with severe hypoglycemia. Here's what the evidence shows so far.
Researchers have reported success in a single patient who received cells reprogrammed to produce insulin, reducing her need for insulin injections. Here's what the early report shows—and what remains unknown.
A company is testing genetically modified insulin-producing cells designed to evade the immune system, with early results showing one patient producing insulin without requiring immunosuppressive drugs.
Vertex Pharmaceuticals reported that 10 of 12 study participants became insulin-independent for at least one year using transplanted cells made in the laboratory. All participants required ongoing immunosuppression medication to prevent rejection.
A major obstacle prevents transplanted insulin-producing cells from surviving in the body. Researchers are now developing ways to protect these grafts from immediate immune attack.
Scientists are working to create artificial pancreatic tissue that could one day replace damaged insulin-producing cells without the need for donor organs or lifelong immunosuppression. A new review examines where this technology stands and what challenges remain.
Researchers have developed a method to coax bone marrow stem cells into forming structures that resemble pancreatic islets, offering a potential new source for transplant research and drug testing.
A new study of Spanish adults with Type 1 diabetes finds that people with stronger cooking knowledge and healthier cooking habits tend to have better blood sugar control. The research suggests that teaching practical cooking skills could be a valuable part of diabetes education.
The FDA has approved teplizumab, marking the first medication shown to delay the development of type 1 diabetes in people at high risk. This approval represents a significant milestone in diabetes prevention, though the drug delays rather than prevents the disease.
A new partnership aims to advance cell-based approaches to treating Type 1 diabetes. The collaboration brings together a biotech company and one of the nation's leading medical centers.
Eledon Pharmaceuticals presented updated findings from an investigator-initiated trial testing tegoprubart in patients with Type 1 diabetes who received islet cell transplants. The data was shared at the 2026 American Diabetes Association Scientific Sessions.
Scientists at Joslin Diabetes Center are collaborating on a multi-pronged approach to understand and potentially reset the immune system in Type 1 diabetes. The work focuses on how T cells develop and why they mistakenly attack insulin-producing cells.
Early clinical trial results from Vertex Pharmaceuticals suggest that replacing damaged insulin-producing cells with healthy transplanted ones may help people with Type 1 diabetes reduce or stop insulin injections.
Scientists are using CRISPR gene editing to create insulin-producing cells from mesenchymal stromal cells that might better evade immune rejection in Type 1 diabetes patients. This approach aims to overcome one of the biggest obstacles to cell-based diabetes treatments.
Researchers have successfully converted cells in the gastrointestinal tract into insulin-producing cells in laboratory and animal studies. This discovery could one day lead to a renewable source of replacement cells for people with Type 1 diabetes.
A new study finds that cooking competency—the ability to prepare meals from scratch and understand nutrition labels—is linked to eating fewer ultra-processed foods in people with Type 1 diabetes.
Scientists discovered that pancreatic ductal cells can activate the immune system when exposed to inflammatory signals, offering new insights into how Type 1 diabetes develops. This finding may help researchers understand disease progression and explore new prevention approaches.
Researchers developed an injectable material that delivers oxygen and growth factors to transplanted insulin-producing cells, addressing a major barrier to islet transplant success in mice. The approach showed promise in early testing but remains far from clinical use.
Researchers are testing a staining technique that makes transplanted islets visible under a microscope, which could improve how doctors monitor whether transplants are working in patients with Type 1 diabetes.
A Type 1 diabetic shares her decision to move from insulin pens to an automated pump after 20 years of managing her condition. Her story highlights both the challenges of diabetes management and the practical considerations that led her to explore new technology.
Mount Sinai's Obesity, Diabetes and Metabolism Institute is pursuing research into therapies that could help regenerate insulin-producing beta cells. Here's what the institute's leadership is working toward.
Researchers are testing a procedure that transplants insulin-producing cells into the liver, with some patients reducing or stopping insulin injections. Early results are encouraging, but significant hurdles remain.
A participant in an early-stage trial at the University of Chicago received transplanted pancreatic islet cells combined with an immune-protecting drug. We look at what the experience reveals about a potential future treatment approach.
Research in mice suggests that pairing an immune-modulating antibody with a compound that supports beta cell health may offer stronger protection against Type 1 diabetes than either treatment alone.
Breakthrough T1D highlights major presentations from the American Diabetes Association's annual scientific meeting. Here's what researchers shared about the latest Type 1 diabetes advances.
New research confirms that teplizumab helps preserve insulin-producing cells in people with stage 2 type 1 diabetes, delaying the progression to stage 3. The medication works by reducing the body's attack on these critical cells.
A detailed case study shows that type 1 diabetes developing after haploidentical stem cell transplantation may sometimes arise from a patient's own residual immune cells rather than from donor cells—a finding that could reshape how doctors understand and prevent post-transplant diabetes.
Immunotherapies represent a fundamentally new approach to Type 1 diabetes by targeting the immune attack on insulin-producing cells rather than just managing blood sugar. Recent advances highlight how scientists are working to slow or stop the destruction that drives the disease.
Researchers are working to grow insulin-producing cells from stem cells to replace those damaged by Type 1 diabetes. While the science is advancing, significant hurdles remain before this approach reaches patients.
Two very different autoimmune diseases share surprising similarities in how they attack the body. Researchers are using that overlap to develop better targeted therapies for both conditions.
Scientists are learning that the energy factories inside cells play a crucial role in developing insulin-producing cells from stem cells. Understanding this process could improve transplant therapies for Type 1 diabetes.
Scientists at Mount Sinai have identified a new class of drugs that appear capable of prompting human pancreatic beta cells to regenerate. The work represents a shift in thinking about whether beta cell renewal is possible in diabetes.
A podcast discussion features a woman with Type 1 diabetes who has reduced her daily insulin to just a few units after 13 years of dependence. We explore what her story tells us and what questions remain.
A new encapsulated cell replacement therapy being tested in Canada uses a protective pouch to keep donor insulin-producing cells alive and functional. Early safety results suggest the approach may be viable.
Breakthrough T1D has awarded funding to support a clinical trial investigating whether SAB-142 can help preserve remaining insulin production in people with newly diagnosed Type 1 diabetes.
New data from a major diabetes conference and a comprehensive review of immunotherapy studies show that teplizumab can slow the progression of Type 1 diabetes in newly diagnosed people. Here's what the evidence actually demonstrates.
A new study from Vertex shows that lab-grown insulin-producing cells helped 10 out of 12 patients achieve insulin independence. The advancement offers hope, but important questions about long-term safety remain.
Researchers have developed a new approach to islet transplantation that combines insulin-producing cells with blood vessel cells in a supportive scaffold, showing promise in early animal studies for restoring normal blood sugar control.
Researchers found that adding a specific type of immune cell during the development of lab-grown insulin-producing cells makes them mature faster and work more effectively when transplanted into diabetic mice.
Scientists used advanced imaging to study what happens when stem cell-made insulin-producing cells are transplanted into the body. The findings show important differences between using a person's own cells versus donor cells.
Researchers developed a specialized nanofibrous scaffold that helps insulin-producing islet cells survive and function when transplanted under the skin. The approach worked well in mice and may one day offer a less invasive way to treat Type 1 diabetes.
Researchers reviewed years of published studies on porcine islet xenotransplantation for Type 1 diabetes and found a surprising gap: there's almost no guidance on how to properly inform patients before they participate in these experimental procedures.
Vertex Pharmaceuticals has announced changes to its Type 1 diabetes programs. Here's what the update means for the research landscape.
New studies tracking people who received teplizumab reveal how the treatment performs outside clinical trials and what patients and caregivers actually experience.
A private placement funding round will help support NewcelX Ltd.'s work on a Type 1 diabetes program. The company is among many organizations exploring new approaches to the disease.
A pediatric center in Canada has achieved a first-time milestone in type 1 diabetes treatment. Learn what this advancement means for young patients and families.
Researchers have successfully transplanted 80 million engineered cells into a patient with type 1 diabetes in a procedure that did not trigger immune rejection. This marks a significant milestone in cell therapy research for diabetes.
Islet xenotransplantation—using animal cells to replace insulin-producing tissue—shows promise as an alternative to lifelong insulin therapy. But scientists and ethicists are working to address significant questions about animal welfare, consent, and fairness.
A new study reveals the behind-the-scenes research that helped bring teplizumab to approval. Understanding how scientists overcame testing challenges offers insight into how immunotherapies are developed.
A medication has been approved to delay Type 1 diabetes onset. Here's what that means and how researchers are building on this progress.
Researchers at TrialNet and elsewhere are studying ways to prevent or delay Type 1 diabetes onset. Dr. Michael Haller discusses how these prevention studies are progressing and what they might mean for newly diagnosed patients.
Researchers are investigating whether neighboring pancreas cells can be converted into insulin-producing beta cells using a simple peptide injection—a potential path toward restoring natural insulin production in Type 1 diabetes.
A parent shares how their child's mood and emotional well-being changed after receiving stem cell treatment for Type 1 diabetes. While personal stories offer hope, they reflect individual experiences rather than proven outcomes.
A participant in the EladON trial shares her story of receiving an islet cell transplant alongside Teplizumab treatment. We look at what her experience reveals about this emerging approach.
Islet transplantation represents an evolving approach to type 1 diabetes management. Here's what you need to know about how this research is developing.
A small trial is testing whether transplanted insulin-producing cells, protected by a new drug approach, can reduce or eliminate the need for insulin injections in people with Type 1 diabetes.
The FDA has approved Tzield for use in people with stage 3 Type 1 diabetes. Here's what the approval represents and why it matters to the community.
Researchers are developing ways to grow insulin-producing cells in the laboratory and transplant them back into people with Type 1 diabetes. Here's what the science shows so far—and what questions remain.
A Canadian research team is investigating ways to help transplanted insulin-producing cells survive longer in the body. Here's what they're working on and why it matters.
Researchers have discovered that a small population of T cells marked by two specific proteins—LEF1 and TCF1—sustain the autoimmune attack in type 1 diabetes. Understanding these stem-like immune cells could point toward new ways to stop the disease before it takes hold.
A YouTube video documents one person's blood sugar experience after a pig islet cell transplant. Here's what we know—and what we need before drawing any conclusions.
A participant in the Eledon trial has reduced her daily insulin requirement to just a few units—a significant change that highlights ongoing research into slowing or halting Type 1 diabetes progression. We spoke with her about her experience.
Scientists are exploring whether the insulin-producing beta cells damaged in Type 1 diabetes can be regenerated. Here's what the current research landscape looks like and why this question matters.
Scientists at Joslin Diabetes Center are exploring a coordinated approach to Type 1 diabetes that targets the immune system malfunction and beta cell loss simultaneously. The strategy rests on three key steps: reset, regulate, and regenerate.
Two biotech companies announced a collaboration to launch clinical trials of a gene-edited cell replacement approach. Here's what this partnership means for the Type 1 diabetes community.
The Australasian Type 1 Diabetes Immunotherapy Collaborative held its first town hall to connect patients, families, and clinicians around emerging immunotherapy approaches. The event highlighted the growing focus on immune-based treatments in the region.
Researchers are investigating whether multipotent stromal cells—immune cells from bone marrow—can trigger beta cell regeneration and reduce blood sugar levels in Type 1 diabetes. Early evidence from animal studies and early clinical trials is encouraging, though many questions remain.
A major follow-up study tracking thousands of people over nearly two decades found no serious safety concerns with immunotherapy drugs designed to delay type 1 diabetes onset. The results clear the way for further research—though these drugs do not cure or reverse the disease.
A person living with Type 1 diabetes for three decades walks through the practical steps of replacing an Omnipod 5 pod. Here's what the real-world process involves.
A new partnership brings together researchers at UMass, Harvard, and Jackson Laboratory to study how the immune system destroys insulin-producing cells—and how to replace them.
Scientists are exploring ways to help the body's insulin-producing cells multiply. Here's what early work in this area tells us.
A comprehensive review of 30 years of stem cell research shows two main approaches gaining ground: replacing damaged beta cells and calming the immune system. Here's where the field stands today.
Multiple therapies in development are advancing toward the goal of reducing or eliminating insulin dependence for people with Type 1 diabetes. Researchers describe the current state of the pipeline as making 'remarkable progress.'
A new drug offers the first approach to actually slow the progression of Type 1 diabetes rather than just manage it. Here's what you need to know about this milestone treatment.
Scientists are learning more about what happens inside the pancreas of people with Type 1 diabetes by studying donated tissue samples. This research could help advance future treatments.
A new JDRF Center of Excellence brings together researchers from UMass Chan Medical School, Harvard, and Jackson Laboratory to study how Type 1 diabetes develops—work that could eventually lead to better treatments.
Researchers are studying a special strain of mice that naturally develops Type 1 diabetes to understand how the immune system attacks insulin-producing cells. These insights are helping guide the development of new immunotherapies that could one day prevent or slow disease onset in people.
Recent breakthroughs in immunotherapy and gene editing offer hope for delaying Type 1 diabetes and preserving insulin-producing cells—moving medicine beyond insulin management toward addressing what causes the disease.
Two leading companies announced a clinical trial partnership to test a novel approach: using CRISPR gene editing to create replacement cells for Type 1 diabetes treatment. Here's what we know about this early-stage research.
A new study reveals that young adults with Type 1 diabetes experience significant burden from their care routines and report moderate quality of life. The findings highlight where support is needed most.
New research reveals that CD8 T cells attacking the pancreas in Type 1 diabetes have a specific, recognizable trait: they react directly to beta cells. This discovery could help researchers develop better ways to monitor and target the immune cells driving the disease.
Mayo Clinic has announced a collaboration with Sana Bio focused on developing cell-based therapies for Type 1 diabetes. The partnership includes a financial investment from Mayo Clinic in the biotech company.
Researchers are investigating new approaches to help insulin-producing cells survive and function better after transplantation, a key step toward making cell-based treatments more effective for people with Type 1 diabetes.
The company has been selected to share preclinical data on CNTY-813, an experimental Type 1 diabetes treatment, at two significant 2026 conferences focused on diabetes research and care.
Researchers are launching a new clinical trial to evaluate whether specially engineered immune cells can help preserve insulin production in people with type 1 diabetes. The approach represents an experimental strategy distinct from existing approved therapies.
Researchers have identified a unique subset of pancreatic beta cells that persist in people with established Type 1 diabetes, offering clues about how some cells escape immune attack. Understanding these surviving cells could point toward new strategies for prevention and disease reversal.
JDRF is strategically funding clinical trials and new research projects to develop therapies that can slow or prevent Type 1 diabetes. Here's how the research pipeline works to move the field forward.
NewcelX has appointed Dr. Camillo Ricordi, a pioneering figure in diabetes research, to help guide the development of new Type 1 diabetes therapies.
The organization formerly known as JDRF is pursuing cure research alongside practical improvements to daily diabetes management. Here's how they're working across multiple fronts to transform the field.
A University of Chicago study combined islet cell transplantation with teplizumab to help one person discontinue insulin therapy. Here's what her case reveals about where Type 1 treatment research stands.
A newly approved monoclonal antibody can delay when Type 1 diabetes develops in people at high risk. It buys time without insulin—but it is not a cure.
LADA, or latent autoimmune diabetes in adults, is a rare form of Type 1 diabetes that develops slowly and often goes misdiagnosed. Understanding its features can help people get the right treatment.
Researchers at a diabetes center are exploring a combined strategy to address why single-approach clinical trials have had limited long-term success. The collaboration examines how combining multiple immune-targeting methods might offer more sustained benefit.
A participant in a University of Chicago study combined transplanted islet cells with the drug teplizumab and achieved insulin independence. Her experience offers a real-world look at what's involved in this experimental approach.
A new approach to islet cell transplantation combined with a targeted immunosuppressive drug has allowed six Type 1 diabetes patients to stop taking insulin. The trial is expanding to enroll more participants.
Researchers are exploring a novel strategy to treat Type 1 diabetes by retraining the immune system to stop attacking beta cells rather than replacing them. Imcyse, a Belgian biotech company, is developing immunotherapies designed to restore immune tolerance.
The Australasian Type 1 Diabetes Immunotherapy Collaborative held its first town hall to discuss immunotherapy research and clinical trials. Here's what you need to know about this new community initiative.
A viral video makes bold promises about Type 1 diabetes and CRISPR gene editing, but lacks the scientific evidence needed to inform our community.
Researchers are exploring ways to protect and strengthen the insulin-producing cells that often survive even years after a Type 1 diabetes diagnosis. Understanding what remains could open new treatment possibilities.
Teplizumab represents a shift in how we approach Type 1 diabetes by targeting the disease process itself rather than just managing blood sugar. Here's what this milestone means for the community.
Even as newer CF treatments improve lung function, cystic fibrosis related diabetes remains a growing challenge. Scientists are exploring genetic factors, nutrition, and stem cell research to better prevent and manage the condition.
Researchers are investigating ways to replace the insulin-producing beta cells that the immune system destroys in Type 1 diabetes. These approaches offer potential new treatment directions, though significant work remains ahead.
The FDA has granted accelerated approval to Tzield (teplizumab) based on stage 3 trial data, marking a significant milestone in efforts to delay Type 1 diabetes onset in at-risk individuals.
A participant in a clinical trial combining islet cell transplantation with Teplizumab shares what life has been like six months after the procedure, including what it means to live without insulin injections.
Researchers followed people with Type 1 diabetes who received islet cell transplants and found that while most maintained stable vision, rapid blood sugar improvement triggered temporary eye changes in some patients.
Researchers are documenting a rare but serious side effect: Type 1 diabetes developing in patients receiving immune checkpoint inhibitor therapy for cancer. Understanding this connection could help doctors identify at-risk patients earlier.
Researchers at Joslin Diabetes Center are pursuing an approach that tackles Type 1 diabetes from three angles at once: stopping immune attacks on beta cells, preventing them from restarting, and restoring the body's natural insulin-producing capacity.
Researchers, patients, and advocates share a common goal: finding better treatments and ultimately a cure for Type 1 diabetes. Progress depends on sustained effort and collaboration across the entire community.
Recent breakthroughs in stem cell transplantation, beta-cell preservation, and regeneration are opening new possibilities for people with Type 1 diabetes. Here's what the latest research shows.
A major funding organization is backing continued research into SAB-142 beyond its first 100 days of treatment. Here's what we know about this next phase of investigation.
New data from Vertex's ongoing study reveals that 10 of 12 patients with Type 1 diabetes remained insulin-independent for a full year after receiving VX880 therapy. The results come with an important trade-off: all participants require immunosuppressive medications to maintain the benefit.
For the first time, a new class of drugs is offering a way to delay Type 1 diabetes onset—marking a significant shift in how the disease can be managed. Several clinical trials are now testing immunotherapies that could open the door to new prevention and treatment strategies.
A comprehensive review of five clinical trials shows teplizumab can preserve insulin-producing cells and reduce insulin needs in newly diagnosed Type 1 diabetes, though benefits decline over time.
Researchers and doctors have long discussed the possibility of breakthroughs for Type 1 diabetes—but what does the current research landscape actually show? Here's a breakdown of the science behind prevention and intervention studies, and what different research goals actually mean.
Researchers are working to understand and identify warning signs for a rare form of type 1 diabetes that can develop in cancer patients receiving immune checkpoint inhibitor treatment.
A viral video claims stem cells have cured Type 1 diabetes in individual patients. Here's what the evidence actually shows—and what questions remain.
Breakthrough T1D has released a strategic plan to move cell-based treatments from the lab into clinical trials faster. The roadmap addresses key obstacles that have slowed progress toward regenerative therapies for Type 1 diabetes.
Stem cell treatments are being offered internationally for Type 1 diabetes, but robust scientific evidence about their safety and effectiveness remains limited. Here's what patients and families should consider.
The organization formerly known as JDRF supports research across several different approaches—from immune therapies to cell replacement—alongside tools that help people manage diabetes day-to-day.
Researchers and clinicians are exploring whether stem cell treatments can repair damage caused by Type 1 diabetes, but questions remain about whether they represent a cure or a repair strategy. A closer look at what stem cells can and cannot do.
Type 1 diabetes changes lives immediately upon diagnosis. Breakthrough T1D, a major research and support organization, offers practical resources and community connection for newly diagnosed patients and longtime living with the condition.